Drug class

Low dose Aspirin (81 mg or less)

Rather than an established standalone therapeutic class, "Low dose Aspirin (81 mg or less)" represents a specific dosage-defined administrative grouping within the broader antiplatelet and nonsteroidal anti-inflammatory drug (NSAID) classes. Read more about Low dose Aspirin (81 mg or less)

130 drugs in this class 67 manufacturers

Advertisement

Drugs in Low dose Aspirin (81 mg or less)

Showing 118–126 of 130 drugs

ASPIRIN EC (aspirin)

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES · MYOCARDIAL REINFARCTION PREVENTION ·+11
FT-STRATEGIC SO

ASPIRIN

LOW DOSE ASPIRIN (81 MG OR LESS) · MYOCARDIAL INFARCTION PREVENTION ·+1
L Perrigo Company

ASPIRIN

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES · ACUTE MYOCARDIAL INFARCTION ·+16
AMERISOURCE-GNP

ASPIRIN EC (aspirin)

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES · MYOCARDIAL REINFARCTION PREVENTION ·+11
AMERISOURCE-GNP

ASPIRIN

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES · ACUTE MYOCARDIAL INFARCTION ·+16
INNOVIDA PHARMA

ASPIRIN

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES · MYOCARDIAL INFARCTION PREVENTION ·+1
GENDOSE PHARMAC

ASPIRIN EC (aspirin)

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES · MYOCARDIAL REINFARCTION PREVENTION ·+11
GENDOSE PHARMAC

ASPIRIN EC (aspirin)

LOW DOSE ASPIRIN (81 MG OR LESS) · MYOCARDIAL REINFARCTION PREVENTION ·+11
HEB GROCERY COM

ASPIRIN EC (aspirin)

LOW DOSE ASPIRIN (81 MG OR LESS) · MYOCARDIAL REINFARCTION PREVENTION ·+11
AARNA USA INC
Filter & compare in the drug finder → Opens the drug finder with Low dose Aspirin (81 mg or less) preselected. Add indication or manufacturer filters there.

About Low dose Aspirin (81 mg or less).

Rather than an established standalone therapeutic class, "Low dose Aspirin (81 mg or less)" represents a specific dosage-defined administrative grouping within the broader antiplatelet and nonsteroidal anti-inflammatory drug (NSAID) classes.

At these lower doses, aspirin selectively and irreversibly acetylates cyclooxygenase-1 (COX-1), which suppresses platelet production of thromboxane A2 and thereby inhibits platelet aggregation.

Formulations in this category are primarily utilized for cardioprotective and antithrombotic therapy, including the secondary prevention of cardiovascular and cerebrovascular events, as well as risk reduction in high-risk obstetric conditions like preeclampsia.